Routine Laboratory Testing Data for Surveillance of Rotavirus Hospitalizations to Evaluate the Impact of Vaccination

  title={Routine Laboratory Testing Data for Surveillance of Rotavirus Hospitalizations to Evaluate the Impact of Vaccination},
  author={Manish M Patel and Jacqueline e. Tate and Rangaraj Selvarangan and Irini Daskalaki and M. A. Jackson and Aaron T. Curns and Susan E. Coffin and Barbara M Watson and Richard L. Hodinka and Roger I Glass and Umesh D. Parashar},
  journal={The Pediatric Infectious Disease Journal},
Objective: The recent implementation of a rotavirus vaccination program in the United States makes it imperative to assess the impact of immunization on the incidence of severe rotavirus disease leading to hospitalization. Active surveillance for laboratory-confirmed rotavirus hospitalizations is the ideal approach for surveillance, but requires substantial resources to implement. We examined laboratory and hospital discharge data for 2 tertiary care pediatric hospitals to assess the utility of… 
Burden of Childhood Rotavirus Disease on Health Systems in the United States: Results From Active Surveillance Before Rotavirus Vaccine Introduction
Before the widespread use of rotavirus vaccines in the United States, rotav virus was prevalent among children treated in hospital-based and outpatient settings and was associated with a substantial proportion of pediatric medical visits for AGE.
Hospital-Based Surveillance to Estimate the Burden of Rotavirus Gastroenteritis Among European Children Younger Than 5 Years of Age
Most community-acquired rotavirus gastroenteritis occurs in children aged <2 years, and a high proportion occurs in infants aged <6 months, and cases were also observed among very young infants <2 months of age.
Hospital-based Surveillance to Evaluate the Impact of Rotavirus Vaccination in São Paulo, Brazil
After vaccine implementation, a marked decline in rotavirus AGE hospitalizations was demonstrated among children younger than 5 years of age, with the greatest reduction in the age groups targeted for vaccination.
Temporal Changes in Pediatric Gastroenteritis after Rotavirus Vaccination in Quebec
Norovirus infections were more prevalent than rotavirus infections among pediatric gastroenteritis cases hospitalized or seeking emergency care, andRotavirus cases were, on average, more clinically severe than norovirus cases among participants of the same age.
Trends in Healthcare Utilization for Diarrhea and Rotavirus Disease in Privately Insured US Children <5 Years of Age, 2001–2006
Rotavirus causes substantial health and economic burden in US children, especially in ED and outpatient settings, and future monitoring through claims-based data sources should allow assessment of rotavirus vaccine impact on healthcare utilization for diarrhea.
Projected Impact of the new rotavirus vaccination program on hospitalizations for gastroenteritis and rotavirus disease among US children <5 years of age during 2006-2015.
Vaccination is expected to substantially reduce the health burden of hospitalizations for rotavirus disease among US children during 2006-2015, and the impact of vaccination based on direct protective effects alone was expected to first occur for hospitalization for AGE among infants during winter 2009.
Rotavirus-associated acute gastroenteritis hospitalizations among Japanese children aged <5 years: active rotavirus surveillance in Mie Prefecture, Japan.
The findings confirm the substantial health burden of rotavirus AGE hospitalization among Japanese children <5 years of age and the most dominant rotav virus genotype was G3P[8], which accounted for 73.1% of cases.
Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama.
  • V. Bayard, R. DeAntonio, R. Colindres
  • Medicine, Political Science
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2012
All-cause gastroenteritis and rotavirus-coded hospitalizations among US children, 2000-2009.
Since implementation of the US rotavirus vaccination program, a marked reduction in diarrhea hospitalizations and related hospital charges has occurred among US children.


Estimates of the burden of rotavirus disease in Malaysia.
There is a significant burden associated with AG- and rotav virus disease-related hospitalizations and outpatient visits among Malaysian children, and this burden potentially could be prevented by the use of rotavirus vaccines.
The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden.
A rotavirus vaccine program will require improved surveillance, including the timely collection of data from sentinel hospitals, in which a diagnosis of rotav virus can be established or ruled out for all children hospitalized for diarrhea.
Evaluation of rotavirus vaccine effectiveness in a pediatric group practice.
The authors aimed to estimate the effectiveness of a rotavirus vaccine (rhesus rotvirus vaccine-tetravalent (RRV-TV) to prevent rotav virus-related hospitalization among children <or=3 years of age.
Disease burden and risk factors for hospitalizations associated with rotavirus infection among children in New York State, 1989 through 2000
In New York State diarrhea is a common hospital discharge diagnosis and contributes ∼13% of all hospitalizations among children <5 years of age, and when hospitals with maximum recording were used as a reference point, >30% of diarrhea hospitalizations were recorded as likely the result of rotavirus.
Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
The Advisory Committee on Immunization Practices recommends routine vaccination of U.S. infants with 3 doses of this rotavirus vaccine administered orally at ages 2, 4, and 6 months.
Pediatric viral gastroenteritis during eight years of study
Rotavirus-infected patients tended to be younger during the months of greatest rotav virus activity than at the beginning and end of the rotavirus season, presumably because of a greater exposure to virus at the height of the Rotavirus outbreak.
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts, and the risk of intussusception was similar in vaccine and placebo recipients.
Field evaluation of vaccine efficacy.
The epidemiological techniques available for measuring vaccine efficacy are described and a practical approach to their use is recommended, including screening, outbreak investigations, secondary attack rates in families or clusters, vaccine coverage assessment, and case-control studies.